Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Ovarian Epithelial 3

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × CCV-AV protocol × Gynecologic × Clear all
NCT01617629 2017-12-08

CAN-003X

Prima BioMed Ltd

Phase 2 Completed
9 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01068509 2017-05-11

Ovarian Cancer Vaccine for Patients in Remission

Prima BioMed Ltd

Phase 2 Completed
63 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01521143 2016-12-14

CANVAS

Prima BioMed Ltd

Phase 2 Terminated
91 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡